Eligi
Med
Ensayos clínicos
Suscripción
Sobre EligiMed
Ensayos Clínicos de Oncología | EligiMed
Ensayos clínicos
8.676 ensayos encontrados
Reclutando
Fase 2
ClinicalTrials.gov
A Randomized Phase II, Double-blind, Multicenter Study Evaluating the Efficacy and Safety of Autogene Cevumeran Plus Nivolumab Versus Nivolumab as Adjuvant Therapy in Patients With High-risk Muscle-invasive Urothelial Carcinoma
INTERVENTIONAL
Inicio: 9 de dic de 2024
ID: NCT06534983
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared With Standard of Care as First-line Intervention in Participants With Metastatic Esophageal Carcinoma
INTERVENTIONAL
Inicio: 28 de jul de 2021
ID: NCT04949256
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Program to Evaluate the Efficacy and Safety of MK-7240 in Participants With Moderately to Severely Active Ulcerative Colitis
INTERVENTIONAL
Inicio: 25 de oct de 2023
ID: NCT06052059
Completado
Fase 2
ClinicalTrials.gov
A Phase II Study of Dasatinib Therapy in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or With Ph+ Leukemias Resistant or Intolerant to Imatinib
INTERVENTIONAL
Inicio: 20 de mar de 2009
ID: NCT00777036
Retirado
ClinicalTrials.gov
Regional Anesthesia in Patients Undergoing Colon-Rectal Surgery
INTERVENTIONAL
Inicio: 1 de dic de 2007
ID: NCT00684229
Completado
Fase 1
ClinicalTrials.gov
Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
INTERVENTIONAL
Inicio: 16 de feb de 2015
ID: NCT02303821
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3 Randomized Study of Loncastuximab Tesirine Combined With Rituximab Versus Immunochemotherapy in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-5)
INTERVENTIONAL
Inicio: 16 de sept de 2020
ID: NCT04384484
Completado
Fase 3
ClinicalTrials.gov
A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy
INTERVENTIONAL
Inicio: 29 de ene de 2013
ID: NCT01721876
Activo, no recluta
Fase 3
ClinicalTrials.gov
An Open-label, Randomised, Phase III Study cOmparing trifLuridine/Tipiracil (S 95005) in Combination With Bevacizumab to Capecitabine in Combination With Bevacizumab in firST-line Treatment of Patients With metastatIC Colorectal Cancer Who Are Not candidatE for Intensive Therapy (SOLSTICE Study)
INTERVENTIONAL
Inicio: 21 de mar de 2019
ID: NCT03869892
Completado
Fase 3
ClinicalTrials.gov
The BURAN Study of Buparlisib (AN2025) In Combination With Paclitaxel Compared to Paclitaxel Alone, in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
INTERVENTIONAL
Inicio: 12 de dic de 2020
ID: NCT04338399
Terminado
Fase 3
ClinicalTrials.gov
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
INTERVENTIONAL
Inicio: 20 de sept de 2019
ID: NCT04066491
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination With Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination With Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYVIBE-008)
INTERVENTIONAL
Inicio: 24 de mar de 2022
ID: NCT05224141
Completado
Fase 3
ClinicalTrials.gov
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy
INTERVENTIONAL
Inicio: 1 de dic de 2008
ID: NCT00806819
Completado
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
INTERVENTIONAL
Inicio: 21 de feb de 2011
ID: NCT01234337
Completado
Fase 4
ClinicalTrials.gov
Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia
INTERVENTIONAL
Inicio: 1 de abr de 1995
ID: NCT00411541
Terminado
Fase 2
ClinicalTrials.gov
An Open-Label, Multicenter Phase 1/2 Dose Escalation and Expansion Study of THOR-707 as a Single Agent and as a Combination Therapy in Adult Subjects With Advanced or Metastatic Solid Tumors
INTERVENTIONAL
Inicio: 20 de jun de 2019
ID: NCT04009681
Completado
Fase 2
ClinicalTrials.gov
A Phase 2, Single-Arm Study of Pralatrexate in Patients With Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
INTERVENTIONAL
Inicio: 1 de jul de 2008
ID: NCT00722553
Completado
Fase 3
ClinicalTrials.gov
A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC)
INTERVENTIONAL
Inicio: 28 de jun de 2019
ID: NCT03976323
Completado
Fase 3
ClinicalTrials.gov
A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer
INTERVENTIONAL
Inicio: 9 de jul de 2013
ID: NCT01828099
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)
INTERVENTIONAL
Inicio: 5 de ago de 2021
ID: NCT04960709
Anterior
1
...
58
59
60
...
434
Siguiente
Filtros